


FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G




FIG. 1H




FIG. 1I




FIG. 1J




FIG. 1K




FIG. 2



100A
200A
110a
152
154
210a
140
240
120
130a
230a
220
110a
156
210a
140
240
120
130a
230a
220

FIG. 3A



100B
200B
162
164
140
240
120
110b
210b
220
166

FIG. 3B



100C
110a
162
172
210a
200C
140
240
120
130b
230b
220
182

FIG. 3C



100B
162
172
210a
200C
140
240
120
110b
230b
220
182

FIG. 3D



300A
400A
350
310
450
410
330
430
420
320
340a
440a
300B
400B
340b
440b
300C
400C
340c
440c

FIG. 4




FIG. 5A




FIG. 5B




FIG. 6



500
600
700A
640
510
620
520
530
630
670
720
540
740
560
610
710

FIG. 7A



500
600
700B
640
510
620
712
520
530
630
672
720
540
740
560
610
730

FIG. 7B

800A




FIG. 8A

800B




FIG. 8B



800C
T1
T1
E1
E1
CH2
CH2
810
810
CH3
CH3

FIG. 8C



800D
E1
E1
CH2
CH2
810
810
CH3
CH3
T1
T1

FIG. 8D



800E
T1
T1
CH2
CH2
810
810
CH3
CH3
E1
E1

FIG. 8E



800F
T1
T1
825
825
V_L
V_H
V_L
V_H
830
C_K
CH1
C_K
CH1
820
820
CH2
CH2
810
810
CH3
CH3
E1
E1

FIG. 8F



900A
T2
T1
T1
T2
CH2
CH2
910
910
CH3
CH3
E1
E1

FIG. 9A



900B
E2
E1
E1
E2
CH2
CH2
910
910
CH3
CH3
T1
T1

FIG. 9B




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13



200
100
0
-100
-200
-300
-400
0
5
10
15
20
25
30
min

FIG. 14



Intensity x 10^6
6
5
4
3
2
1
0
1083.7833
1084.0336
1083.5323
1084.2845
1083.2804
1084.7858
1084.5358
1085.0343
1083.25
1083.75
1084.25
1084.75
m/z

FIG. 15




FIG. 16A




FIG. 16B



964.7324
964.4804
964.9830
964.2305
965.2339
965.7240
965.9745
965.4747
966.2262
Intensity x 10⁵
5
4
3
2
1
963.5
964.0
964.5
965.0
965.5
966.0
966.5
967.0
m/z

FIG. 17



924.4664
924.2991
924.6336
924.1318
924.8007
924.9672
923.9644
925.1330
Intensity x 10⁶
4
3
2
1
0
923.8
924.2
924.6
925.0
925.4
m/z

FIG. 18



2264.1934
2263.1920
2265.1938
2266.1927
100
80
60
40
20
0
Relative Abundance
2262
2263
2264
2265
2266
2267
m/z

FIG. 19



4000
3000
2000
1000
0
0
5
10
15
20
25
30
min

FIG. 20



2000
1500
1000
500
7803
6000
8000
10000
m/z

FIG. 21



Emission intensity (AU)
2000
1500
1000
500
0
300
400
500
600
700
800
Wacelength (nm)

FIG. 22




FIG. 23




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 26D




FIG. 26E




FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 30A




FIG. 30B




FIG. 30C




FIG. 30D




FIG. 30E



Intensity
400
300
200
100
0
8801
8200
8600
9000
9400
9800
m/z

FIG. 31



2500
2000
1500
1000
500
0
53694
56949
48000
52000
56000
60000
64000
m/z

FIG. 32




FIG. 33




FIG. 34A




FIG. 34B




FIG. 35




FIG. 36A




FIG. 36B



anti-CD79b scFv
Linker unit with 3 anti-CD79b scFv
Joint linker with 3 anti-CD79b scFv and 5 DM1
OD450
3
2
1
0
huCD79a-Fc
huCD79b-Fc

FIG. 37



170
130
100
72
55
43
34
26
170
130
100
72
55
43
34
26
#1

FIG. 38



300
200
100
0
Intensity
14917
16381
14000
15000
16000
m/z

FIG. 39



80
60
40
20
0
Intensity
12654
12000
14000
16000
m/z

FIG. 40



170
130
100
72
55
43
34
26
17
#1
#2
#3
1
2
3
4

FIG. 41



Crude LPS
Purified LPS
Dansyl-conjugated LPS
A drug bundle of LPS
1.5
1.0
0.5
0.0
OD620
0
50
100
Concentration (ng/ml)

FIG. 42



Imiquimod
PEG5-NHS-conjugated imiquimod
OD620
2.0
1.5
1.0
0.5
0.0
0
5
10
15
20
Concentration (μM)

FIG. 43



OD450
4
3
2
1
0
0hr
2hr
4hr
24hr
48hr
72hr
PBS
anti-VEGF-A scFv
Linker unit with 2 anti-VEGF-A scFv and 20-kDa PEG

FIG. 44



10000
8000
6000
4000
2000
RFU
4
6
8
11
16
log2
DM1 only
Drug bundle of 5 DM1
Linker unit with 3 anti-CD79b scFv
Joint linker with 3 anti-CD79b scFv and 5 DM1

FIG. 45



1
2
170
130
100
70
55
40
35
25

FIG. 46




FIG. 47A




FIG. 47B




FIG. 48A




FIG. 48B




FIG. 49A




FIG. 49B




FIG. 50




FIG. 51A




FIG. 51B




FIG. 52A




FIG. 52B




FIG. 53A




FIG. 53B




FIG. 54A




FIG. 54B




FIG. 55A



Human SPARC
Human RANKL
HSA
OD450
1.5
1.0
0.5
0.0
Denosumab-
(scFv α SPARC)
Denosumab
α-SPARC

FIG. 55B




FIG 56




FIG 57



1
2
3
4
5
30 min
3 hr
28 hr
4.0
3.0
2.0
1.0
x10^9
Color Scale
Min = 2.01e8
Max = 4.38e9

FIG. 58




FIG. 59A




FIG. 59B




FIG. 60A




FIG. 60B




FIG. 61A




FIG. 61B




FIG. 62A




FIG. 62B




FIG. 62C




FIG. 62D




FIG. 62E




FIG. 63



(A) EGF-hIgG.Fc-Cys
(B) EGF-hIgG.Fc-scFvαPD-1
(C) EGF-hIgG.Fc-scFvαCD3
(D) EGF(S2W/D3V)-hIgG.Fc-Cys
(E) EGF(S2W/D3V)-hIgG.Fc-scFvαCD3
10⁰ 10¹ 10² 10³ 10⁴
FITC-A

FIG. 64



(A) EGF-hIgG.Fc-scFv a PD-1
(B) Anti-PD-1 Ab
(C) EGF(S2W/D3V)-hIgG.Fc-(scFv a PD-1)
(D) EGF-hIgG.Fc-scFv a CD3
(E) OKT3 mAb
(F) EGF(S2W/D3V)-hIgG.Fc-(scFv a CD3)
FITC-A

FIG. 65




FIG. 66A




FIG. 66B




FIG. 66C




FIG. 66D




FIG. 67A




FIG. 67B




FIG. 67C




FIG. 68